Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Mesoblast’s Cell Therapy For Pediatric GVHD Gets US Panel Green Light Despite FDA's "Substantial Concerns"
Mesoblast's remestemcel-L data is sufficient to support efficacy, FDA panel concludes • Source: Shutterstock
More from US FDA Performance Tracker
More from Regulatory Trackers